A Systematic Review to Define the Multi-Faceted Role of Lysine Methyltransferase SETD7 in Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 25

PMID 35326563

Authors

Fatima Liliana Monteiro

Cecilia Williams

Luisa A Helguero

Affiliations

Soon will be listed here.

Abstract

Histone-lysine N-methyltransferase SETD7 regulates a variety of cancer-related processes, in a tissue-type and signalling context-dependent manner. To date, there is no consensus regarding SETD7´s biological functions, or potential for cancer diagnostics and therapeutics. In this work, we summarised the literature on SETD7 expression and function in cancer, to identify the contexts where SETD7 expression and targeting can lead to improvements in cancer diagnosis and therapy. The most studied cancers were found to be lung and osteosarcoma followed by colorectal and breast cancers. SETD7 mRNA and/or protein expression in human cancer tissue was evaluated using public databases and/or in-house cohorts, but its prognostic significance remains inconclusive. The most studied cancer-related processes regulated by SETD7 were cell proliferation, apoptosis, epithelial-mesenchymal transition, migration and invasion with special relevance to the pRb/E2F-1 pathway. SETD7 consistently prevented epithelial to mesenchymal transition in different cancer types, and inhibition of its function appears to be associated with improved response to DNA-damaging agents in most of the analysed studies. Stabilising mutations in SETD7 target proteins prevent their methylation or promote other competing post-translational modifications that can override the SETD7 effect. This indicates that a clear discrimination of these mutations and competing signalling pathways must be considered in future functional studies.

Citing Articles

Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring.

Shannar A, Sarwar M, Dave P, Chou P, Peter R, Xu J Mol Biol Rep. 2024; 51(1):1139.

PMID: 39522095 PMC: 11551078. DOI: 10.1007/s11033-024-10033-6.

SETD7 Promotes Cell Proliferation and Migration via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma.

Zhang J, Duan B, Li F, Jing X, Li R, Cai S Int J Biol Sci. 2024; 20(8):3008-3027.

PMID: 38904013 PMC: 11186372. DOI: 10.7150/ijbs.93201.

Lysine-specific methyltransferase Set7/9 in stemness, differentiation, and development.

Daks A, Parfenyev S, Shuvalov O, Fedorova O, Nazarov A, Melino G Biol Direct. 2024; 19(1):41.

PMID: 38812048 PMC: 11137904. DOI: 10.1186/s13062-024-00484-z.

Unravelling the molecular mechanistic pathway underlying the anticancer effects of kaempferol in colorectal cancer: a reverse pharmacology network approach.

Priyamvada P, Ashok G, Joshi T, Anbarasu S, Anbarasu A, Ramaiah S Mol Divers. 2024; 29(2):1049-1067.

PMID: 38795259 DOI: 10.1007/s11030-024-10890-0.

ACAT2 suppresses the ubiquitination of YAP1 to enhance the proliferation and metastasis ability of gastric cancer via the upregulation of SETD7.

Zhang M, Cai F, Guo J, Liu S, Ma G, Cai M Cell Death Dis. 2024; 15(4):297.

PMID: 38670954 PMC: 11053133. DOI: 10.1038/s41419-024-06666-x.

References

Chen Y, Yang S, Hu J, Yu C, He M, Cai Z . Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma. PLoS One. 2016; 11(5):e0154939. PMC: 4868314. DOI: 10.1371/journal.pone.0154939. View

Zhou J, Xie M, Shi Y, Luo B, Gong G, Li J . MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. Oncol Rep. 2015; 34(1):111-20. DOI: 10.3892/or.2015.3952. View

Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B . The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol Cell. 2011; 43(4):681-8. DOI: 10.1016/j.molcel.2011.08.007. View

. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2017; 46(D1):D8-D13. PMC: 5753372. DOI: 10.1093/nar/gkx1095. View

Oudhoff M, Braam M, Freeman S, Wong D, Rattray D, Wang J . SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling. Dev Cell. 2016; 37(1):47-57. DOI: 10.1016/j.devcel.2016.03.002. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Zhang X, Huang Y, Shi X . Emerging roles of lysine methylation on non-histone proteins. Cell Mol Life Sci. 2015; 72(22):4257-72. PMC: 11114002. DOI: 10.1007/s00018-015-2001-4. View

Vasileva E, Shuvalov O, Petukhov A, Fedorova O, Daks A, Nader R . KMT Set7/9 is a new regulator of Sam68 STAR-protein. Biochem Biophys Res Commun. 2020; 525(4):1018-1024. DOI: 10.1016/j.bbrc.2020.03.017. View

Hou Z, Min W, Zhang R, Niu A, Li Y, Cao L . Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. Bioorg Med Chem Lett. 2020; 30(9):127061. DOI: 10.1016/j.bmcl.2020.127061. View

10.

Lee J, Shao N, Paik D, Wu H, Guo H, Termglinchan V . SETD7 Drives Cardiac Lineage Commitment through Stage-Specific Transcriptional Activation. Cell Stem Cell. 2018; 22(3):428-444.e5. PMC: 5929163. DOI: 10.1016/j.stem.2018.02.005. View

11.

Pradhan S, Chin H, Esteve P, Jacobsen S . SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics. 2009; 4(6):383-7. PMC: 2974562. DOI: 10.4161/epi.4.6.9450. View

12.

Cao L, Ren Y, Guo X, Wang L, Zhang Q, Li X . Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway. Int J Mol Med. 2020; 45(5):1616-1626. DOI: 10.3892/ijmm.2020.4523. View

13.

Castano J, Morera C, Sese B, Boue S, Bonet-Costa C, Marti M . SETD7 Regulates the Differentiation of Human Embryonic Stem Cells. PLoS One. 2016; 11(2):e0149502. PMC: 4758617. DOI: 10.1371/journal.pone.0149502. View

14.

Romeo S, Zeni O, Sannino A, Lagorio S, Biffoni M, Scarfi M . Genotoxicity of radiofrequency electromagnetic fields: Protocol for a systematic review of in vitro studies. Environ Int. 2021; 148:106386. DOI: 10.1016/j.envint.2021.106386. View

15.

Song Y, Zhang J, Tian T, Fu X, Wang W, Li S . SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer. Tumour Biol. 2016; 37(7):9311-22. DOI: 10.1007/s13277-016-4822-7. View

16.

Batista I, Helguero L . Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer. Signal Transduct Target Ther. 2018; 3:19. PMC: 6043541. DOI: 10.1038/s41392-018-0017-6. View

17.

Bultman S . SETD7 interacts with other chromatin-modifying factors to regulate cardiac development. Stem Cell Investig. 2019; 6:14. PMC: 6624362. DOI: 10.21037/sci.2019.05.03. View

18.

Francis N, Rowlands M, Workman P, Jones K, Aherne W . Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screen. J Biomol Screen. 2012; 17(8):1102-9. DOI: 10.1177/1087057112452137. View

19.

Song H, Chu J, Park S, Im H, Park I, Kim H . Isoform-Specific Lysine Methylation of RORα2 by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression. Int J Mol Sci. 2020; 21(5). PMC: 7084544. DOI: 10.3390/ijms21051622. View

20.

Duan B, Bai J, Qiu J, Wang J, Tong C, Wang X . Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients. EBioMedicine. 2018; 37:134-143. PMC: 6284455. DOI: 10.1016/j.ebiom.2018.10.036. View